Showing results (161-170 of 171) with videos related to
Sort By:
Pageof 18
Journal of the Peripheral Nervous System : JPNS|June 27, 2015
Grip strength comparison in immune-mediated neuropathies: Vigorimeter vs. JamarThomas H P Draak, Mariëlle H J Pruppers, Sonja I van Nes, et al.Nature Genetics|December 17, 2013
Loss-of-function mutations in MICU1 cause a brain and muscle disorder linked to primary alterations in mitochondrial calcium signalingClare V Logan, György Szabadkai, Jenny A Sharpe, et al.Arthritis & Rheumatology (Hoboken, N.J.)|March 13, 2019
Galectin-9 and CXCL10 as Biomarkers for Disease Activity in Juvenile Dermatomyositis: A Longitudinal Cohort Study and Multicohort ValidationJudith Wienke, Felicitas Bellutti Enders, Johan Lim, et al.BMC Medicine|March 3, 2022
Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseasesLuuk Wieske, Laura Y L Kummer, Koos P J van Dam, et al.The Lancet. Neurology|March 20, 2021
Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trialChrista Walgaard, Bart C Jacobs, Hester F Lingsma, et al.Journal of Autoimmunity|January 9, 2023
Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinationsKoos P J van Dam, Luuk Wieske, Eileen W Stalman, et al.BMC Infectious Diseases|May 17, 2023
Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activityKoos P J van Dam, Adriaan G Volkers, Luuk Wieske, et al.Annals of the Rheumatic Diseases|November 10, 2022
Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseasesEileen W Stalman, Luuk Wieske, Koos P J van Dam, et al.The Lancet. Rheumatology|March 23, 2022
Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort studyLuuk Wieske, Koos P J van Dam, Maurice Steenhuis, et al.The Journal of Allergy and Clinical Immunology|May 19, 2024
Clinical and humoral response after SARS-CoV-2 breakthrough infection in patients receiving immunosuppressant therapyEileen W Stalman, Luuk Wieske, Jim B D Keijser, et al.Pageof 18